Efficacy and Safety of Enteric-Coated Mycophenolate Sodium in De Novo and Maintenance Renal Transplant Patients

Transplantation Proceedings

Volumn 40, Issue 1, 2008, Pages 189-192

  Nart, A ^a   Sipahi, S ^a   Aykas, A ^a   Uslu, A ^a   Hoscoskun C ^a   Toz, H ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; BASILIXIMAB; COTRIMOXAZOLE; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CHRONIC GRAFT REJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GINGIVA HYPERPLASIA; GLOMERULONEPHRITIS; GRAFT INFECTION; GRAFT REJECTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFORMED CONSENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAINTENANCE THERAPY; MALE; ORGAN DONOR; OXALOSIS; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; RESPIRATORY TRACT INFECTION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; ZONA ZOSTER;

ADULT; AZATHIOPRINE; CREATININE; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; SAFETY; TABLETS, ENTERIC-COATED;

EID: 38749090915     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2007.11.066     Document Type: Article

References (9)

1. Sollinger H.W., and US Renal Transplant Mycophenolate Renal Transplant Study Group. Mycophenolate mofetil for the prevention of acute rejection in cadaveric renal allograft recipients. Transplantation 60 (1995) 225
2. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized, clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61 (1996) 1029
3. Ojo A.O., Meier-Kiersche H.U., and Hanson J.A. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69 (2000) 2405
4. Knoll G.A., MacDonald I., and Khan A. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 14 (2003) 2381
5. Johnston A., He X., and Holt D.W. Bioequivalence of enteric coated mycophenolate sodium and mycophenolate mofetil: a meta-analysis of three studies in stable renal transplant recipients. Transplantation 82 (2006) 1413
6. Pelletier R.P., Akin B., and Henry M.L. The impact of mycophenolate mofetil dosing pattern on clinical outcome after renal transplantation. Clin Transplant 17 (2002) 200
7. Rostaing L., Mourad G., Kamar N., et al., French Myriad FR01 Study Group. Tolerability of enteric-coated mycophenolate sodium to 1 year in combination with cyclosporin and corticosteroid in renal transplant recipients. Transplant Proc 38 (2006) 2860
8. Vogt B., Antoniadis A., Klinger M., et al. Efficacy and safety of enteric-coated mycophenolate sodium (myfortic) in de novo renal transplant recipients: Results of a 12-month multicenter, open label, prospective study. Transplant Proc 38 (2006) 1306
9. Pietruk F., Abbud-Filho M., Vathsala A., et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable maintenance renal transplant patients: Pooled results from three international, multicenter studies. Transplant Proc 39 (2007) 103